Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High mobility group box 1 (HMGB1) levels in the placenta and in serum in preeclampsia.

American journal of reproductive immunology (New York, N.Y. : 1989)·2011
Same author

Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene.

Intervirology·2011
Same author

[Clinicopathological features of primary splenic histiocytic sarcoma: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2011
Same author

[Comparison of treatment with micro endoscopic discectomy and posterior lumbar interbody fusion using single and double B-Twin expandable spinal spacer].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2011
Same author

Virtual transplantation in designing a facial prosthesis for extensive maxillofacial defects that cross the facial midline using computer-assisted technology.

The International journal of prosthodontics·2011
Same author

Total synthesis of phorboxazole A via de novo oxazole formation: convergent total synthesis.

Journal of the American Chemical Society·2010

Related Experiment Video

Updated: Mar 17, 2026

Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
07:52

Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts

Published on: April 26, 2018

9.5K

Elevated E2F7 expression predicts poor prognosis in human patients with gliomas.

WenWen Yin1, Bo Wang1, MaoHua Ding2

  • 1The First People's Hospital of Xuzhou, No.19, North Zhongshan Road, Quanshan District, Xuzhou, Jiangsu Province 221002, China.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|July 28, 2016
PubMed
Summary

E2F7 expression is elevated in gliomas and correlates with tumor grade and recurrence. This atypical E2F transcription factor shows potential as an independent prognostic factor for glioma progression-free survival and a therapeutic target.

Keywords:
CDK1E2F7GliomaPrognosisTumor grade

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

3.2K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 17, 2026

Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
07:52

Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts

Published on: April 26, 2018

9.5K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

3.2K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • E2F transcription factors regulate crucial cellular processes like cell cycle and apoptosis.
  • E2F7, an atypical member, is understudied in glioma pathogenesis.
  • Gliomas are primary brain tumors with varying grades and outcomes.

Purpose of the Study:

  • To investigate E2F7 expression in gliomas.
  • To correlate E2F7 levels with clinicopathological features and patient outcomes.
  • To explore E2F7 as a potential prognostic marker and therapeutic target in gliomas.

Main Methods:

  • Analysis of E2F7 mRNA levels using the Oncomine database.
  • Immunohistochemical validation of E2F7 and CDK1 expression in 90 gliomas.
  • Univariate and multivariate Cox regression analyses for prognostic evaluation.

Main Results:

  • E2F7 mRNA levels are significantly elevated in gliomas compared to normal brain tissue.
  • E2F7 expression increases with glioma grade and correlates positively with CDK1.
  • Higher E2F7 expression is associated with tumor grade and recurrence, and predicts progression-free survival.

Conclusions:

  • E2F7 is upregulated in gliomas and linked to aggressive tumor characteristics.
  • E2F7 serves as an independent prognostic factor for progression-free survival in glioma patients.
  • E2F7 represents a potential therapeutic target for glioma treatment.